Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) announced its earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), FiscalAI reports. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The company had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS traded up $2.98 during trading hours on Monday, reaching $69.59. The stock had a trading volume of 1,279,659 shares, compared to its average volume of 583,685. The company has a market cap of $2.95 billion, a price-to-earnings ratio of -34.45, a PEG ratio of 0.96 and a beta of 0.57. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The business’s fifty day moving average is $72.54 and its two-hundred day moving average is $68.01. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25.

Insiders Place Their Bets

In other news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the sale, the insider directly owned 38,958 shares in the company, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The SEC filing for this sale provides additional information. 8.97% of the stock is owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Deep Track Capital LP raised its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares in the last quarter. Janus Henderson Group PLC grew its position in Tarsus Pharmaceuticals by 34.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock valued at $158,062,000 after acquiring an additional 491,326 shares during the period. MPM Bioimpact LLC acquired a new position in Tarsus Pharmaceuticals during the second quarter worth $13,834,000. Franklin Resources Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 1,419.3% during the fourth quarter. Franklin Resources Inc. now owns 337,016 shares of the company’s stock valued at $27,595,000 after acquiring an additional 314,833 shares during the period. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Tarsus Pharmaceuticals by 86.1% during the second quarter. Qube Research & Technologies Ltd now owns 459,436 shares of the company’s stock valued at $18,612,000 after acquiring an additional 212,592 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TARS. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Barclays started coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective on the stock. Mizuho started coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price for the company. Finally, Zacks Research raised Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $82.29.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.